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Background: Increasing rates of non-AIDS defining illnesses, and in particular liver diseases, have been found after
the initiation of highly active antiretroviral therapy. However, there is little evidence concerning the risk factors for
and clinical characteristics of liver disease in antiretroviral (ARV)-treated HIV infection, in the absence of hepatitis B
or C viral co-infection.
Methods: A nested case–control study of HIV infected volunteers, matched by starting date of anti-retroviral
treatment, was conducted in a Thai cohort studied from Nov 2002 - July 2012. Cases were defined as those
subjects with an elevated alanine aminotransferase (ALT ≥ 40 IU/L) at two consecutive visits six months apart, while
controls were defined as individuals who never demonstrated two consecutive elevated ALT results and had a
normal ALT result (< 40 IU/L) at their last visit. Both groups had normal ALT levels prior to ARV initiation. Clinical
demographics and risk factors for chronic hepatitis including HIV-related illness, ARV treatment and metabolic
diseases were collected and analyzed. Conditional logistic regression was used to determine risk factors for chronic
hepatitis in HIV infection.
Results: A total of 124 matched pairs with HIV infection were followed over 3,195 person-years. The mean age
(±SD) was 33.0 ± 7.3 years, with 41.1% of subjects being male. The incidence of chronic hepatitis was 5.4 per 100
person-years. The median time from initiation of ARV to chronic hepatitis was 1.3 years (IQR, 0.5-3.5). From
univariate analysis; male sex, plasma HIV-1 RNA level > 5 log 10 copies/ml, metabolic syndrome at baseline visit, high
BMI > 23 kg/m2, abnormal HDL cholesterol at time of ALT elevation and treatment experience with NNRTI plus
boosted PI were selected (p value < 0.2) to the final model of multivariate analysis. Male sex had 3.1 times greater
risk of chronic hepatitis than the females by multivariate analysis (adjusted OR, 95% CI: 3.1, 1.5-6.3, p =0.002). High
BMI ≥ 23 kg/m2 was also associated with 2.4 times greater risk of chronic hepatitis (adjusted OR, 95% CI: 2.4, 1.2-4.8,
p = 0.01).
Conclusions: Chronic hepatitis in ARV-treated HIV-infected patients is common and may lead to a major health
care problem. Male sex and high BMI ≥ 23 kg/m2 carry higher risks for developing chronic hepatitis in this study.
Therefore, these patients should be closely monitored for long-term hepatotoxicity.
Keywords: Chronic hepatitis, HIV infection, Risk factors* Correspondence: nhiransu@gmail.com
1Department of Preventive and Social Medicine, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand
Full list of author information is available at the end of the article
© 2013 Chalermchai et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Chalermchai et al. AIDS Research and Therapy 2013, 10:21 Page 2 of 9
http://www.aidsrestherapy.com/content/10/1/21Background
Human immunodeficiency virus (HIV) infection continues
to be a major global health problem. An estimated 33.4 mil-
lion people are currently living with HIV worldwide [1].
The era of highly active antiretroviral therapy (HAART) for
the treatment of HIV-infected individuals has led to a dra-
matic reduction in AIDS-defining illnesses and mortality
[2]. However, an inverse trend has also been observed with
increasing rates of non-AIDS defining illnesses including
liver diseases manifesting themselves in the context of lon-
ger life expectancy [3,4]. Little is known about the risk fac-
tors for and clinical characteristics of liver disease in Asian
HIV infection. Manifestations of liver disease in HIV infec-
tion include mild, asymptomatic rises in liver transaminase
levels, chronic steatohepatitis, liver cirrhosis and more se-
vere forms resulting in hepatic failure. In general, chronic
liver disease in HIV mono-infected patients usually present
with no or only mild symptoms and rising serum trans-
aminase levels [5]. Research into the HIV-infected sub-
group with mildly elevated transaminase levels is so far
minimal. Previous studies suggested that the majority of
mild, asymptomatic chronic hepatitis in HIV infection were
undiagnosed [5]. Failure or delay in the diagnosis and treat-
ment of liver disease in HIV infection may result in long-
term liver morbidities such as chronic steatohepatitis, liver
cirrhosis or hepatocellular carcinoma and, importantly, may
also increase the rate of liver-related mortality [6].
The etiologies of liver disease seen in HIV infection in-
clude hepatitis B or C virus co-infection, medication-
induced hepatitis from antiretroviral (ARV) or non-ARV
drugs (such as anti-tuberculous and anti-lipemic agents),
metabolic syndrome, excessive alcohol consumption and
HIV infection itself [3].
ARV medications that commonly result in rising trans-
aminase in HIV infection include stavudine (d4T), nevi-
rapine (NVP) and high dose ritonavir (RTV) [7-9].
Other reported risk factors were being men who has sex
with men (MSM), and having a history of arterial
hypertension or a body mass index (BMI) greater than
25 kg/m2 [9-11].
Chronic hepatitis in HIV infection has also been asso-
ciated with poor HIV-specific treatment outcomes, such
as current CD4+ T-lymphocyte counts < 200 cells/mm3
and detectable HIV-1 RNA levels [11].
Previous studies of chronic hepatitis in HIV infection
were mostly cross-sectional. Most of the studies were
conducted in developed countries. There is a lack of
clinical evidence in developing countries especially in
patients treated with ARV. Results from this study will
support healthcare personnel in understanding and
selecting appropriate treatment for a resource-limited
setting.
This study aims to determine clinical demographic
and the risk factors of chronic hepatitis in ARV-treated,HIV-infected Thai patients without hepatitis B or C co-
infection who were followed longitudinally for up to
10 years.
Materials and methods
We conducted a nested case–control study utilizing data
from a long term observational study (Clinical trial.gov,
NCT 00411983) for HIV-infected individuals who had
previously participated in clinical studies and continued
into a long term cohort after the completion of the spe-
cific study. The study participants were scheduled for
follow-up at The HIV Netherlands Australia Thailand
Research Collaboration or HIV-NAT clinic in Bangkok,
Thailand on a semi-annual basis to monitor their long-
term outcomes for AIDS-defining and non-AIDS defin-
ing illnesses as well as adverse events from ARV treat-
ment. Medical history, physical examination and history
of ARV treatment were recorded. Subjects underwent
blood draw for complete blood count (CBC), serum ala-
nine aminotransferase level (ALT) and serum creatinine
level. CD4+ T lymphocyte counts and HIV-1 RNA levels
were also measured at each study visit.
Our study focused on liver complications in HIV with-
out hepatitis B or C co-infection. The inclusion criteria
were HIV-infected individuals, older than 18 years of
age, negative hepatitis B surface antigen (HBs Ag) or
HBV DNA and negative HCV antibody (anti-HCV) or
HCV RNA. Exclusion criteria were patients who did not
have a recorded viral hepatitis serology result, had an ab-
normal ALT level at their baseline visit or prior to ARV
treatment (ALT ≥40 IU/L), unavailable baseline ALT
level or had less than 12 months of follow up. Written,
informed consent was obtained from all enrollees. This
specific study was approved by the Ethics Committee of
the Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand.
For this case–control study, the cases, or chronic
hepatitis was defined as those with elevated ALT ≥
40 IU/L at 2 consecutive visits 6 months apart after the
initiation of ARV [7,8]. The controls was defined as
those patients who never had two consecutive ALT ≥
40 IU/L and still had normal ALT at the last visit. Both
groups had normal ALT at pre-ARV initiation (baseline).
The case and control were matched 1:1 for duration
from ARV initiation (± 6 months).
All clinical data and laboratory testing for comparison
were selected by utilizing data at baseline and at the
time chronic hepatitis occurred in the cases and the data
at the same period (± 6 months) for the matched
controls.
All analytic data for this study were censored on July
1, 2012.
The duration of the study was calculated from the
time of initiation of ARV to the last follow-up visit.
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time of ARV initiation to the diagnosis of chronic
hepatitis.
Definitions
HIV infection was defined by a positive result for HIV-
specific antibodies by enzyme-linked immunosorbent
assay (ELISA) and/or HIV-1 RNA by the Roche
Amplicor HIV-1 Monitor Test v1.5.
Hepatitis B virus infection was defined by a positive
result for HBsAg using the ARCHITECT HBsAg quali-
tative assay (ABBOTT Max-Planck-Ring 2, Germany)
and/or detectable HBV DNA by polymerase chain reac-
tion (PCR).
Hepatitis C virus infection was defined by a positive
result for HCV-specific antibodies using the ARCHI-
TECT Anti-HCV assay or detectable HCV RNA by PCR.
Severity grading of chronic hepatitis was classified
according to the following ranges of ALT level: grade 1,
1.0 – 2.5 times the upper limit of normal (1.0-2.5 ×
ULN); grade 2, 2.6–5.0 × ULN; grade 3, 5.1–10 × ULN;
grade 4, >10 × ULN. Severe hepatitis was defined by at
least grade 3 ALT elevation [12].
Severity of HIV infection was classified by Centers for
Disease Control and Prevention (CDC) 1993 guidelines
[13].
Body mass index (BMI) was calculated as weight in ki-
lograms divided by height in meters squared. BMI cat-
egories specific for Asian individuals were assigned as
follows: BMI <18.5 (underweight), BMI = 18.5 – 22.9
(normal), BMI = 23–24.9 (overweight) and BMI ≥25.0
(obese) [14].HIV infected individuals from HIV-NAT long 
(n=1,680)
HIV  infection without 
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Figure 1 Demonstrate flow of the study.Dyslipidemia was defined as serum triglyceride level ≥
150 mg/dL, HDL-cholesterol ≤ 40 mg/dL for males, ≤
50 mg/dL for females, LDL-cholesterol ≥ 130 mg/dL and
total cholesterol ≥200 mg/dL [15,16].
Elevated blood pressure was defined as a systolic blood
pressure > 130 mmHg or diastolic blood pressure >
85 mmHg, or known history of hypertension [16].
Impaired fasting plasma glucose was defined as a
fasting plasma glucose ≥ 100 mg/dL or known history of
diabetes mellitus [16].
Metabolic syndrome was defined as having at least 3 of
5 criteria serum triglyceride level ≥150 mg/dL, serum
HDL-cholesterol ≤40 mg/dL for male or ≤50 mg/dL for
females, elevated blood pressure, impaired fasting
plasma glucose and BMI ≥ 23 kg/m2 or waist circumfer-
ence ≥ 90 cm. for male or ≥ 80 cm. for females [14].
Clinically-diagnosed lipodystrophy was defined as
those with lipoatrophy or lipohypertrophy, truncal obes-
ity or facial lipodystrophy [17].
The main risk factors that were evaluated included
clinical characteristics [age, gender, sexual risk behavior,
HIV-related illness and disease severity, baseline CD4+ T
lymphocyte counts, plasma HIV-1 RNA level and meta-
bolic diseases] and clinical parameters and laboratory as-
sessments at an event visit [previous history of ARV
treatment, concomitant medications, clinical and labora-
tory findings of HIV-related illnesses and metabolic
diseases].
Statistical and data analysis
Clinical characteristics were described as frequency and
percentage for categological data. Continuous data wereterm cohort
Inactive status 
(referral to local treatment centers,
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Table 1 Characteristics of chronic hepatitis in cases of
HIV patients with chronic non HBV/HCV hepatitis*
Clinical parameters Case
(n =124 )
Incidence rate , per 100 person-years 5.4
Median (IQR), duration from starting ARV to
hepatitis, years
1.3(0.5–3.5)
Mean ALT level at time of ALT elevation, IU/L (±SD) 73 ± 107
Mean AST level at time of ALT elevation, IU/L (±SD) 58 ± 49
Mean alkaline phosphatase level at time of ALT
elevation, IU/L (±SD)
97 ± 54
Severity grading of chronic hepatitis **, n (%)
o Mild (grade 1 or 2) 122 (98.4)
o Severe, at least grade 3 2 (1.6)
Symptoms at time of ALT elevation, n (%)
o Any 64(51.6)




o Weight loss 4(3.2)
o Jaundice 1(0.8)
o Liver tenderness 1(0.8)
Abbreviation: HIV Human immunodeficiency virus, HBV Hepatitis B virus, HCV
Hepatitis C virus, ALT Alanine aminotransferase, AST Aspartate
aminotransferase, SD Standard deviation.
* Chronic hepatitis was defined as those with elevated ALT ≥40 IU/L at 2
consecutive visits 6 months apart.
**Severity grading of chronic hepatitis was classified by using ALT level: grade
1, 1.0 – 2.5 times the upper limit of normal (1.0-2.5 × ULN); grade 2, 2.6–5.0 ×
ULN; grade 3, 5.1–10 × ULN; grade 4, >10 × ULN [12]. Severe hepatitis was
defined as having at least grade 3 ALT level.
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mally distributed or as median and inter-quartile range
(IQR) if not normally distributed [18]. For inferential data
analysis, the McNemar’s test was used for categorical data.
For continuous data, the paired student’s t-test was used if
the data had normal distribution, while the Wilcoxon
signed-rank test was used if they showed non-normal dis-
tribution. Factors with p value less than 0.2 from univariate
analysis were selected to the model of multivariate analysis.
Conditional stepwise, logistic regression was used to evalu-
ate the risk factors of chronic hepatitis. Odds ratio (OR)
and adjusted OR with 95% confidence intervals (CI) were
reported to demonstrate an association between significant
factors with chronic hepatitis. Statistical significance was
defined as a p value less than 0.05. We used STATA/LC
version 11.2 for Windows.
Results
A total of 1,680 HIV-infected individuals participated in
the long term HIV-NAT cohort during the period of No-
vember 2002 to July 2012. We excluded individuals from
the present study owing to inactive status (referral to
local treatment centers, death or study withdrawal) at
the time of data analysis (n = 413), a confirmed positive
result for chronic hepatitis B or C virus infection
(n = 651), unavailable baseline ALT data (n = 120), base-
line ALT ≥ 40 IU/L (n = 119) and loss to follow-up for at
least 1 year (n = 9) (Figure 1).
Characteristics of chronic hepatitis in cases
There were 124 study cases. An incidence rate of
chronic hepatitis was 5.4 per 100 person-years (Table 1).
The mean ALT level at the time of diagnosis of chronic
hepatitis was 73 ± 107 IU/L [median ALT level was
52 IU/L, (IQR, 46–65)]. There were 98.4% of these indi-
viduals who were initially found to have mild ALT (grade
1 or 2) elevation, while 1.6% (n = 2) were found to have
severe hepatitis. The mean (±SD) AST level was slightly
higher than the normal value (58 ± 49 IU/L). The me-
dian duration from the time of an initiation of ARV to
the diagnosis of chronic hepatitis was 1.3 years (IQR,
0.5-3.5). The following symptoms were reported at time
of ALT elevation; however, their relatedness to ALT ele-
vation cannot be confirmed: nausea and/or vomiting
(24.2%), fatigue (11.3%), anorexia (7.3%), flatulence
(4.0%) and others (4.8%). All were grades 1 or 2. No ab-
normal severe symptoms, liver failure or hepatic enceph-
alopathy was reported.
Baseline demographics
From a total of 124 HIV-infected, matched pairs by the
date of starting ARV treatment were selected. Male gen-
der was more commonly found in the cases than the
controls. The mean ages in the cases and the controlswere similar. The proportion of men who have sex with
men (MSM) were slightly higher in the cases than the
controls with borderline significance (p = 0.08) (Table 2).
Advanced, HIV-related illnesses were found in 11.3%
and 5.6% of the case and control groups respectively.
There was no significant difference in the proportions of
CD4+ cell count less than 200 cells/mm3 and HIV-1
RNA level greater than 5 log 10 copies/ml between the
two groups.
The proportion of individuals with BMI greater than
23 kg/m2 was slightly higher in the cases than the con-
trols but did not reach statistical significant difference
(p = 0.09). There were only 12 patients who met the cri-
teria for metabolic syndrome because of missing data for
lipid profiles and waist circumference. There was no sig-
nificant difference of metabolic syndrome between
groups.
There was no difference in the prevalence of elevated
blood pressure and hypertension, impaired fasting
plasma glucose and lipid profiles between the groups.
Table 2 Clinical characteristics of HIV patients with or without chronic non HBV/HCV hepatitis at baseline visit**
Clinical parameters Case Control p value
(n = 124) (n = 124)
Male sex (n,%) 65(52.4) 37(29.8) 0.001*
Mean age (years), ± SD 32.7 ± 7.4 33.3 ± 7.2 0.56
o ≤ 25 (n,%) 16(12.9) 12(9.7) 0.85
o 25–34.9 (n,%) 68(54.8) 70(56.4)
o 35–44.9 (n,%) 31(25.0) 34(27.4)
o ≥ 45 (n,%) 9(7.3) 8(6.5)
BMI≥ 23 kg/m2 (n,%) 39(31.4) 27(21.8) 0.09
Elevated blood pressure/ hypertension (n,%) 18(14.5) 18(14.5) 1.00
Metabolic syndrome (n,%) 9(7.3) 3(2.4) 0.08
Sexual risk behavior (n,%) 0.08
o Heterosexual 83(66.9) 98(79.0)
o MSM 37(29.9) 23(18.6)
o Others 4(3.2) 3(2.4)
CDC classification (n,%) 0.21
o Category A or B 110(88.7) 117(94.4)
o Category C 14(11.3) 7(5.6)
Laboratory measurement (n,%)
o CD4+ cell count≤ 200 cells/mm3 53(42.7) 50(40.3) 0.66
o Nadir CD4+ cell count≤ 200 cells/mm3 67(54) 67(54) 1.00
o HIV-1 RNA level ≥ 5 log 10 copies/ml 41(33.1) 31(25) 0.13
o Impaired fasting plasma glucose≥ 100 mg/dL 21(16.9) 16(12.9) 0.87
o Total cholesterol≥ 200 mg/dL 25(22.7) 27(24.1) 0.87
o Triglycerides ≥ 150 mg/dL 25(22.7) 26(23.2) 0.88
o HDL cholesterol≤ 40 mg/dL (male) or ≤ 50 mg/dL (female) 55(51.4) 57(52.3) 0.70
o LDL cholesterol≥ 130 mg/dL 2(1.8) 1(0.9) 0.57
Median, duration of study (years) (IQR) 9.6(6.7–11.9) 9.6(6.7–11.9) 0.97
Abbreviation: HIV Human immunodeficiency virus, HBV Hepatitis B virus, HCV Hepatitis C virus, SD Standard deviation, BMI Body mass index, MSM Men who have
sex with men, CDC The centers for disease control and prevention, HDL Cholesterol High density lipoprotein cholesterol, LDL Cholesterol Low density lipoprotein
cholesterol and IQR Interquartile range.
*Significant value with p value less than 0.05.
**Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2 consecutive visits 6 months apart.
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(at event visit)
The proportion of individuals with BMI greater than
23 kg/m2 was significantly higher in the cases (44.4%)
than the controls (20.9%, p = 0.001) (Table 3).
There was no difference in the proportion with indi-
viduals of CD4+ cell count less than 200 cells/mm3,
plasma HIV-1 RNA level greater than 400 copies/ml, el-
evated blood pressure and hypertension, impaired fasting
plasma glucose and metabolic syndrome between the
groups. The cases tended to have lower HDL than the
controls (p = 0.09).
Anti-retroviral regimens
All patients were treated with ARV (Table 4). The
combination of dual nucleoside reverse transcriptaseinhibitors (NRTI) with PI (protease inhibitor) (48.4%) or
non-nucleoside reverse transcriptase inhibitors (NNRTI)
(37.1%) were the most common first regimens. For triple
NRTI, the most common regimen was zidovudine
(ZDV) combined with lamivudine (3TC) plus didanosine
(ddI) (33%). For dual NRTI plus NNRTI, the most com-
mon regimens were efavirenz (EFV) combined with
tenofovir (TDF) plus 3TC (35.7%) and NVP combined
with 3TC and d4T (17.3%). For dual NRTI plus boosted
PI, the most common regimens were saquinavir/ritonavir
combined with 3TC plus TDF (24.4%) and lopinavir/
ritonavir combined with 3TC plus TDF (12.2%). For
NNRTI plus boosted PI, the most common regimen was
indinavir/ritonavir combined with EFV (44.4%).
Eleven patients developed early acute adverse events
from ARV treatment such as severe hepatitis, drug
Table 3 Clinical characteristics of HIV patients with or without chronic non HBV/HCV hepatitis at time of ALT
elevation**
Clinical parameters Case Control p value
(n = 124) (n = 124)
BMI≥ 23 kg/m 2 (n,%) 55(44.4) 26(20.9) 0.001*
Elevated blood pressure/ hypertension (n, %) 24(19.3) 18(14.5) 0.32
Metabolic syndrome (n, %) 3(4.3) 3(3.0) 0.66
Clinically-diagnosed lipodystrophy 14(11.3) 10(8.1) 0.32
Laboratory measurement (n, %)
o CD4+ cell count≤ 200 cells/mm3 15(12.1) 10(8.1) 0.30
o HIV-1 RNA level ≥ 400 copies/ml 11(8.8) 16(9.6) 0.21
o Impaired fasting plasma glucose≥ 100 mg/dL 15(14.1) 10(9.6) 0.21
o Total cholesterol≥ 200 mg/dL 56(50.4) 48(42.8) 0.49
o Triglycerides ≥ 150 mg/dL 40(36.0) 31(27.7) 0.29
o HDL cholesterol≤ 40 mg/dL (male) or ≤ 50 mg/dL (female) 36(34.3) 22(21.6) 0.09
o LDL cholesterol≥ 130 mg/dL 36(34.3) 25(24.5) 0.32
Abbreviation: HIV Human immunodeficiency virus, HBV Hepatitis B virus, HCV Hepatitis C virus, BMI Body mass index, HDL High density lipoprotein and LDL Low
density lipoprotein.
*Significant value with p value less than 0.05.
**Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2 consecutive visits 6 months apart.
Chalermchai et al. AIDS Research and Therapy 2013, 10:21 Page 6 of 9
http://www.aidsrestherapy.com/content/10/1/21hypersensitivity reaction and severe fatigue. ARV was
discontinued and the hepatitis completely resolved. The
new regimens for these patients were used as the first
ARV regimen for our analysis.
Concomitant medication
The concomitant medications were similar between the
2 groups (Table 5).
Risk factor variables for chronic hepatitis
From the univariate analysis; male sex, plasma HIV-1
RNA level > 5 log 10 copies/ml and metabolic syndromeTable 4 Antiretroviral use* of HIV patients with or
without chronic non HBV/HCV hepatitis**
Clinical parameters Case Control p value
(n = 124) (n = 124)
Median, duration of ARV




o Triple NRTIs 18(14.5) - NA
o Dual NRTIs plus NNRTI 46(37.1) 52(41.9) 0.37
o Dual NRTIs plus boosted
PIs
58(46.8) 65(54.4) 0.29
o NNRTIs plus boosted PIs 2(1.6) 7(5.7) 0.12
Abbreviation: NRTIs Nucleoside reverse transcriptase inhibitors, NNRTI Non-
nucleoside reverse transcriptase inhibitor, PIs Protease inhibitors, ARV
Antiretroviral, IQR Interquartile range, NA Non applicable.
* Ever exposed to antiretroviral medication.
**Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2
consecutive visits 6 months apart.at baseline visit, high BMI ≥ 23 kg/m2 and abnormal
HDL cholesterol at time of ALT elevation and treatment
experience with NNRTI plus boosted PI were selected to
the final model of multivariate analysis (Table 6).
From the multivariate analysis, male sex (AOR, 95%
CI; 3.1, 1.5-6.3, p =0.002) and high BMI ≥ 23 kg/m2
(AOR, 95% CI; 2.4, 1.2-4.8, p = 0.01) were the independ-
ent risk factors for chronic hepatitis.Discussion
Our study examined clinical characteristics and the risk
factors of chronic hepatitis by evaluating ALT level as a
surrogate marker. We reported a case–control study of
124 matched pairs, ARV-treated HIV-infected individ-
uals without HBV or HCV infection with a follow-up
time of 3,195 person-years. Our incidence rate of hepa-
titis was slightly higher (5.4 cases per 100 person-years)
than previously reported in Kovari et al. (3.9 cases per
100 person-years) [9].
The ALT elevation in our study was mostly mild
(grade 1–2, 98.4%). There was no report of serious liver
disease or hepatic encephalopathy, however, its long-
term deleterious consequence is not well defined. The
majority of previous studies mainly reported patients
with severe elevation of ALT (≥ 5 times, UNL) who also
tended to have symptomatic disease [19]. In general,
chronic liver disease in HIV usually presents with no or
mild symptoms with rising serum transaminase levels.
Because such individuals are mostly asymptomatic, de-
layed diagnosis is common [5,20]. Delayed diagnosis and
treatment may lead to long term consequences from
Table 5 Concomitant medication use* of HIV patients
with or without chronic non HBV/HCV hepatitis**
Concomitant medications Case Control p value
(n = 124) (n = 124)
o Isoniazid 17(13.7) 22(17.7) 0.36
o Pyrazinamide 7(5.6) 6(4.8) 0.78
o Gemfibrosil 7(5.6) 7(5.6) 1.0
o Fenofibrate 11(8.8) 8(6.5) 0.47
o Simvastatin 7(5.6) 5(4.0) 0.53
o Cotrimoxazole 50(40.3) 50(40.3) 1.0
o Dapsone 4(3.2) 3(2.4) 0.71
o Fluconazole 19(15.3) 14(11.3) 0.30
o Analgesic 14(11.3) 17(13.7) 0.33
Footnote:
* Ever exposed to any concomitant medications.
** Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2
consecutive visits 6 months apart.
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rhosis and importantly liver cancer [21,22].
We found that the median time from ARV initiation
to chronic hepatitis was 1.3 years (IQR, 0.5-3.5) which
was similar to previous report of 1.2 year [9]. As our def-
inition required two consecutive abnormal ALT 6-
month apart, this suggests that early detection of
chronic hepatitis will require monitoring of symptoms
and liver enzymes within the first year of ARV initiation.
Our study confirmed that males had 3.1 times (95%
CI, 1.5-6.3) greater risk of chronic hepatitis than females.
This finding supports the report by Guaraldi G et al. that
non-alcoholic fatty liver disease (NAFLD) was associated
with male sex and elevated ALT level [23]. Previous
study in HIV-negative US adolescents also supported an
association between NAFLD and male sex [24].
Our study concurred that high BMI greater than
23 kg / m2 was associated with 2.4 times (95% CI,Table 6 Univariate and multivariate analysis to evaluate each
HCV hepatitis***
Clinical parameters and ARV
Male sex
BMI≥ 23 kg/m2 at time of ALT elevation
Metabolic syndrome at baseline visit
Plasma HIV-1 RNA level≥ 5 log 10 copies/ml at baseline visit
HDL cholesterol≤ 40 mg/dL (male) or ≤ 50 mg/dL (female) at time of ALT el
Exposure to NNRTIs + boosted PIs regimens
Abbreviation: OR Odds ratio, AOR Adjusted odds ratio, BMI Body mass index, HDL Hi
PIs Protease inhibitors,
*P value less than 0.20 from univariate analysis to the model for multivariable analy
*** Chronic hepatitis was defined as those with elevated ALT ≥ 40 IU/L at 2 consecu1.2-4.8) greater risk of chronic hepatitis. Previous
studies showed that high BMI (>25 kg / m2) and
overt obesity were associated with chronic hepatitis
[5,9,11]. However, this study did not show an effect
of other metabolic components, likely due to missing
information on lipid profiles and waist circumference
to diagnose the metabolic syndrome. The metabolic
syndrome and high BMI can directly cause insulin re-
sistance and impaired fatty acid oxidation in hepato-
cytes and subsequently lead to hepatic cellular injury
[25,26].
Our findings confirmed the study from the Swiss HIV
cohort that HIV-related parameters such as baseline
CD4+ cell count and HIV-1 RNA level are not associ-
ated with chronic hepatitis. Our finding disagrees with
the study of Sterling et al. which reported that detectable
HIV-1 RNA level was associated with chronic, rising
ALT enzymes. However, that study was a cross-sectional
study. Plasma HIV-1 RNA and ALT level were tested
only one visit during the study period [11].
We did not find exposure to ARV or concomitant
medication to demonstrate an association with chronic
hepatitis in contrast to previous reports [7,10]. The
Swiss cohort reported that chronic elevated ALT levels
were associated with stavudine use of at least 2 years
duration but this study examined only a history of any
ARV exposure, regardless of the duration of that expos-
ure [9].
The strengths of this study include the availability of
prospective longitudinal data collection of ALT that has
been shown to accurately reflect liver steatosis. The de-
termination of chronic hepatitis by using ALT level as a
surrogate laboratory test increases the generalizability of
the data to other resource-limited settings. This test is
inexpensive, widely available and easy to perform. How-
ever, liver injury may exist in the absence of transami-
nases elevation. Limitations of this study include a lack
of histological and clinical imaging data to confirm livervariable and medication for the risk of chronic non HBV/
Univariate p value* Multivariate p value**
OR (95% CI) AOR (95% CI)
3.0(1.6–5.5) <0.001 3.1(1.5–6.3) 0.002*





gh density lipoprotein, NNRTI Non-nucleoside reverse transcriptase inhibitor,
sis **Significant value with p value less than 0.05.
tive visits 6 months apart.
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http://www.aidsrestherapy.com/content/10/1/21injury as well as missing data on alcohol use and param-
eters to diagnose metabolic syndrome. In addition,
lipodystrophy may be under diagnosed or under
reported. This study did not exclude other causes of
chronic hepatitis including metabolic diseases such as
hemochromatosis, Wilson’s disease and autoimmune
hepatitis and infectious causes including cytomegalo-
virus or Epstein-Barr virus, chronic hepatitis E virus. Fi-
nally, this study also did not examine an association
between duration of ARV treatment and chronic hepa-
titis because it had already matched for the date of ARV
initiation.
Conclusion
In conclusion, chronic hepatitis in ARV-treated HIV
infected patients is common and may lead to a major
health care problem. Male sex and high BMI ≥ 23 kg/m2
carry higher risks for developing chronic hepatitis in this
study. Therefore, these patients should be closely moni-
tored for long-term hepatotoxicity.
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